Market Overview

Benzinga's Top Pre-Market Losers

Share:
Related FOLD
Benzinga's Volume Movers
Morning Market Gainers
MEI Pharma Is Undervalued By At Least Half And Will Recover, Here Is Why (Seeking Alpha)
Related GSK
Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices
New Potential HIV Vaccine Drug 'Absolutely 100% Effective' In Monkeys
10 Top Dividend Healthcare Dogs Declare 5% To 20% March Upsides (Seeking Alpha)

Amicus Therapeutics (NASDAQ: FOLD) shares dropped 46.97% to $3.06 in pre-market trading. Amicus Therapeutics and GlaxoSmithKline plc (NYSE: GSK) today announced the 6-month primary treatment period results from the first Phase 3 global registration study.

Allscripts Healthcare Solutions (NASDAQ: MDRX) shares fell 16.48% to $8.92 in the pre-market trading. Allscripts appointed Paul Black as its CEO.

Accenture plc (NYSE: ACN) dipped 5.21% to $66.73 in the pre-market session. Accenture projects Q2 revenue of $6.9 billion of $7.15 billion, versus analysts' estimates of $7.14 billion.

Bed Bath & Beyond (NASDAQ: BBBY) dipped 4.86% to $57.35 in the pre-market session. Bed Bath & Beyond issued downbeat fourth-quarter earnings forecast. The company's board also authorized a new $2.5 billion share repurchase program.

Posted-In: Top Pre-Market LosersNews Movers & Shakers Pre-Market Outlook Markets

 

Related Articles (BBBY + ACN)

Around the Web, We're Loving...